Follicular Lymphoma | Tumor

‘Another Option Available’ for Treatment in Follicular Lymphoma

March 20th 2024, 3:04pm

Article

Treatment with Brukinsa and Gazyva poses a new option for certain patients with follicular lymphoma, with tolerable side effects, an expert told CURE®.

Differing Perspectives on Cancer Treatments

March 14th 2024, 5:00pm

Article

I've learned that there are many differing perspectives when it comes to treatment for cancer, especially from patients to researchers.

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

March 11th 2024, 1:00pm

Podcast

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

FDA Approves Brukinsa, Gazyva Combo for Relapsed, Refractory Follicular Lymphoma

March 7th 2024, 8:54pm

Article

The Food and Drug Administration approved Brukinsa plus Gazyva for patients with relapsed or refractory follicular lymphoma who have undergone two or more prior lines of therapy.

Feeling Better During Cancer Treatment

March 5th 2024, 6:00pm

Article

When I told my friends I started feeling better during cancer treatment, they were all so confused.

Screenings for Different Cancers

February 21st 2024, 6:00pm

Article

Having all of these screenings for cancer terrifies me, even though they could be almost certainly nothing.

Is It a Symptom of Cancer, Injury, Aging, Something Else… Or Nothing?

January 17th 2024, 6:00pm

Article

Whenever I experience a new ache or patch of itchy skin, I immediately think it's a health issue — or a recurrence.

Kymriah Elicits Long-Lasting Responses in R/R Follicular Lymphoma

December 11th 2023, 11:00pm

Article

Researchers reported long-lasting responses and no new safety concerns in patients with relapsed/refractory follicular lymphoma during the 2023 ASH Annual Meeting and Exposition.

Unhelpful Advice I Received During Cancer

November 20th 2023, 11:00pm

Article

Please don’t tell me I have the “good” kind of cancer or comment on how much weight I’ve lost.

Odronextamab Gets Priority Review for Relapsed, Refractory Follicular Lymphoma, DLBCL

October 15th 2023, 7:00pm

Article

The Food and Drug Administration will speed up the review of odronextamab for patients with relasped or refractory follicular lymphoma or diffuse large B-cell lymphoma.